Perrigo to Begin Shipments of Guaifenesin Extended-Release 600mg Tablets, the First Store Brand Equivalents to Mucinex® 600mg

Perrigo to Begin Shipments of Guaifenesin Extended-Release 600mg Tablets, the
   First Store Brand Equivalents to Mucinex® 600mg Extended Release Tablets

PR Newswire

ALLEGAN, Mich., March 18, 2013

ALLEGAN, Mich., March 18, 2013 /PRNewswire/ --Perrigo Company (Nasdaq: PRGO;
TASE) today announced that it has begun shipments of Guaifenesin 600mg
Extended-Release tablets in a launch to its retail and wholesale customers.
This major new product is the first product that is generically equivalent to
Mucinex® 600mg Extended Release tablets.The product will be packaged and
marketed under store and proprietary brands and will be a high quality, value
alternative to Mucinex® 600mg Extended-Release tablets.

(Logo: )

Mucinex® 600mg Extended-Release tablets (Guaifenesin 600mg Extended-Release
Tablets), an expectorant indicated to relieve chest congestion and make coughs
more productive, had sales of approximately $135 million through food, drug
and mass merchandisers for the last 12 months.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This launch is
representative of the Perrigo team's abilities to overcome challenging
circumstances as evidenced by this product's complex formulation and patent
challenges. The team worked diligently to formulate the product, prove the
product's non-infringement to existing patents, validate and achieve
commercial production, and bring the product to market. Perrigo's achievement
represents the first store brand equivalent to be approved by the U.S. Food
and Drug Administration and marketed to consumers as a high quality store
brand product that will represent considerable savings when compared to the
national brand. This is another excellent example of Perrigo's investment and
commitment to making quality healthcare more affordable for our customers."

From its beginnings as a packager of generic home remedies in 1887, Allegan,
Michigan-based Perrigo Company has grown to become a leading global provider
of quality, affordable healthcare products. Perrigo develops, manufactures and
distributes over-the-counter (OTC) and generic prescription (Rx)
pharmaceuticals, infant formulas, nutritional products, pet health, dietary
supplements and active pharmaceutical ingredients (API). The Company is the
world's largest manufacturer of OTC pharmaceutical products for the store
brand market. The Company's primary markets and locations of logistics
operations have evolved over the years to include the United States, Israel,
Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the
Internet (

Note: Certain statements in this press release are forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbor created thereby. These statements
relate to future events or the Company's future financial performance and
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those expressed or
implied by any forward-looking statements. In some cases, forward-looking
statements can be identified by terminology such as "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "potential" or other comparable terminology. The
Company has based these forward-looking statements on its current
expectations, assumptions, estimates and projections. While the Company
believes these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond the
Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year ended
June 30, 2012, as well as the Company's subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made only
as of the date hereof, and unless otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE Perrigo Company

Contact: Arthur J. Shannon, Vice President, Investor Relations and
Communication, +1-269-686-1709,, or Bradley Joseph,
Senior Manager, Investor Relations and Communication, +1-269-686-3373,
Press spacebar to pause and continue. Press esc to stop.